Carboplatin (CB) combined with oral or intravenous (IV) etoposide (ET) for advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC): real-world findings from two European neuroendocrine tumour society centres of excellence
Authors
Frizziero, MelissaSpada, Francesca
Lamarca, Angela
Kordatou, Zoe
Barriuso, Jorge
Nuttall, Christina
McNamara, Mairead G
Hubner, Richard A
Mansoor, Was
Manoharan, Prakash
Fazio, N
Valle, Juan W
Affiliation
Medical Oncology, The Christie NHS Foundation Trust, Manchester, UKIssue Date
2018
Metadata
Show full item recordCitation
Frizziero M, Spada F, Lamarca A, Kordatou Z, Barriuso J, Nuttall C, et al. 1318PCarboplatin (CB) combined with oral or intravenous (IV) etoposide (ET) for advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC): real-world findings from two European neuroendocrine tumour society centres of excellence. Ann Oncol. 2018;29(suppl_8):472.Journal
Annals of OncologyDOI
10.1093/annonc/mdy293.011Additional Links
https://dx.doi.org/10.1093/annonc/mdy293.011Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy293.011